Rory Shallis, MD, Yale Cancer Center, New Haven, CT, addresses the need for standardizing the classification of acute myeloid leukemia (AML) in light of the emergence of two distinct classification systems by the World Health Organization (WHO) and International Consensus Classification (ICC). He emphasizes the importance of eliminating the disparities between these systems to establish clear guidelines for AML diagnosis, which will benefit clinicians and, most importantly, patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.